An Oral Botanical Supplement Improves Small Intestinal Bacterial Overgrowth (SIBO) and Facial Redness: Results of an Open-Label Clinical Study.

IF 4.8 2区 医学 Q1 NUTRITION & DIETETICS Nutrients Pub Date : 2024-09-18 DOI:10.3390/nu16183149
Mildred Min, Dawnica Nadora, Mincy Chakkalakal, Nasima Afzal, Chaitra Subramanyam, Nimrit Gahoonia, Adrianne Pan, Shivani Thacker, Yvonne Nong, Cindy J Chambers, Raja K Sivamani
{"title":"An Oral Botanical Supplement Improves Small Intestinal Bacterial Overgrowth (SIBO) and Facial Redness: Results of an Open-Label Clinical Study.","authors":"Mildred Min, Dawnica Nadora, Mincy Chakkalakal, Nasima Afzal, Chaitra Subramanyam, Nimrit Gahoonia, Adrianne Pan, Shivani Thacker, Yvonne Nong, Cindy J Chambers, Raja K Sivamani","doi":"10.3390/nu16183149","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Small intestinal bacterial overgrowth (SIBO) is a common, yet underdiagnosed, gut condition caused by gut dysbiosis. A previous study has shown the potential of herbal therapy, providing equivalent results to rifaximin.</p><p><strong>Objectives: </strong>The objective of this study was to assess how the use of an oral botanical regimen may modulate the gut microbiome, facial erythema, and intestinal permeability in those with SIBO.</p><p><strong>Methods: </strong>This was an open-label prospective study of adults that had lactulose breath test-confirmed SIBO. Participants received a 10-week oral supplementation of a Biocidin liquid tincture and GI Detox+. If participants were found to be non-responsive to treatment after 10 weeks with a persistently positive lactulose breath test, a third oral supplement, Olivirex, was administered for an additional 4 weeks. Lactulose breath tests were administered at baseline, weeks 6, 10, and 14 to assess for SIBO status. A high-resolution photographic analysis system was utilized to analyze changes in facial erythema. Stool sample collections and venipuncture were performed to analyze the gut microbiome and intestinal permeability.</p><p><strong>Results: </strong>A total of 33 subjects were screened with breath testing, and 19 subjects were found to have SIBO. Three of the subjects withdrew during the screening period prior to baseline, and sixteen subjects enrolled. Four subjects dropped out after baseline. Hydrogen-dominant SIBO was the most common subtype of SIBO, followed by methane and hydrogen sulfide. The botanical regimen was most effective for hydrogen- and hydrogen sulfide-dominant SIBO, leading to negative breath test results at week 10 in 42.8% and 66.7% of participants, respectively. Compared to baseline, supplementation with the botanical regimen led to positive shifts in short-chain fatty acid-producing bacteria such as <i>A. muciniphila</i>, <i>F. prausnitzii</i>, <i>C. eutectus</i>, and <i>R. faecis</i> by 31.4%, 35.4%, 24.8%, and 48.7% percent at week 10, respectively. The mean abundance of <i>Firmicutes</i> decreased by 20.2%, <i>Bacteroides</i> increased by 30%, and the F/B ratio decreased by 25.4% at week 10 compared to baseline. At week 10, there was a trending 116% increase in plasma LPS/IgG (<i>p</i> = 0.08). There were no significant changes in plasma zonulin, DAO, histamine, DAO/histamine, LPS/IgG, LPS/IgA, or LPS/IgM. Facial erythema was not statistically different at week 6, but at week 10, there was a 20% decrease (<i>p</i> = 0.001) in redness intensity. Among the patients that extended to week 14, there was no statistical change in erythema.</p><p><strong>Conclusions: </strong>Supplementation with an antimicrobial botanical supplemental regimen may have therapeutic potential in hydrogen and hydrogen-sulfide subtypes of SIBO. Furthermore, the botanical supplemental regimen may reduce facial erythema, increase SCFA-producing bacteria, decrease the F/B ratio, and modulate markers of intestinal permeability.</p>","PeriodicalId":19486,"journal":{"name":"Nutrients","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11435404/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrients","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/nu16183149","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Small intestinal bacterial overgrowth (SIBO) is a common, yet underdiagnosed, gut condition caused by gut dysbiosis. A previous study has shown the potential of herbal therapy, providing equivalent results to rifaximin.

Objectives: The objective of this study was to assess how the use of an oral botanical regimen may modulate the gut microbiome, facial erythema, and intestinal permeability in those with SIBO.

Methods: This was an open-label prospective study of adults that had lactulose breath test-confirmed SIBO. Participants received a 10-week oral supplementation of a Biocidin liquid tincture and GI Detox+. If participants were found to be non-responsive to treatment after 10 weeks with a persistently positive lactulose breath test, a third oral supplement, Olivirex, was administered for an additional 4 weeks. Lactulose breath tests were administered at baseline, weeks 6, 10, and 14 to assess for SIBO status. A high-resolution photographic analysis system was utilized to analyze changes in facial erythema. Stool sample collections and venipuncture were performed to analyze the gut microbiome and intestinal permeability.

Results: A total of 33 subjects were screened with breath testing, and 19 subjects were found to have SIBO. Three of the subjects withdrew during the screening period prior to baseline, and sixteen subjects enrolled. Four subjects dropped out after baseline. Hydrogen-dominant SIBO was the most common subtype of SIBO, followed by methane and hydrogen sulfide. The botanical regimen was most effective for hydrogen- and hydrogen sulfide-dominant SIBO, leading to negative breath test results at week 10 in 42.8% and 66.7% of participants, respectively. Compared to baseline, supplementation with the botanical regimen led to positive shifts in short-chain fatty acid-producing bacteria such as A. muciniphila, F. prausnitzii, C. eutectus, and R. faecis by 31.4%, 35.4%, 24.8%, and 48.7% percent at week 10, respectively. The mean abundance of Firmicutes decreased by 20.2%, Bacteroides increased by 30%, and the F/B ratio decreased by 25.4% at week 10 compared to baseline. At week 10, there was a trending 116% increase in plasma LPS/IgG (p = 0.08). There were no significant changes in plasma zonulin, DAO, histamine, DAO/histamine, LPS/IgG, LPS/IgA, or LPS/IgM. Facial erythema was not statistically different at week 6, but at week 10, there was a 20% decrease (p = 0.001) in redness intensity. Among the patients that extended to week 14, there was no statistical change in erythema.

Conclusions: Supplementation with an antimicrobial botanical supplemental regimen may have therapeutic potential in hydrogen and hydrogen-sulfide subtypes of SIBO. Furthermore, the botanical supplemental regimen may reduce facial erythema, increase SCFA-producing bacteria, decrease the F/B ratio, and modulate markers of intestinal permeability.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
口服植物补充剂可改善小肠细菌过度生长(SIBO)和面部发红:一项开放标签临床研究的结果。
背景:小肠细菌过度生长(SIBO)是一种常见的肠道疾病,但由于肠道菌群失调而未得到充分诊断。之前的一项研究显示了草药疗法的潜力,其效果与利福昔明相当:本研究旨在评估口服植物疗法如何调节 SIBO 患者的肠道微生物群、面部红斑和肠道通透性:这是一项开放标签前瞻性研究,研究对象是经乳果糖呼气试验证实患有SIBO的成年人。参与者将接受为期10周的Biocidin液体酊剂和GI Detox+口服补充剂治疗。如果10周后发现参与者对治疗无反应,乳糖呼气试验持续呈阳性,则再口服4周第三种补充剂Olivirex。在基线、第 6 周、第 10 周和第 14 周进行乳糖呼气测试,以评估 SIBO 状态。利用高分辨率照片分析系统分析面部红斑的变化。采集粪便样本并进行静脉穿刺,以分析肠道微生物组和肠道通透性:共有 33 名受试者接受了呼气试验筛查,其中 19 名受试者被发现患有 SIBO。其中三名受试者在基线前的筛查期间退出,16 名受试者加入。四名受试者在基线后退出。以氢为主的 SIBO 是最常见的 SIBO 亚型,其次是甲烷和硫化氢。植物疗法对以氢气和硫化氢为主的 SIBO 最有效,分别有 42.8% 和 66.7% 的受试者在第 10 周的呼气试验结果呈阴性。与基线相比,在第 10 周时,补充植物疗法导致短链脂肪酸产生菌(如 A. muciniphila、F. prausnitzii、C. eutectus 和 R. faecis)发生了积极变化,分别增加了 31.4%、35.4%、24.8% 和 48.7%。与基线相比,第 10 周时固醇菌的平均丰度降低了 20.2%,乳酸菌增加了 30%,F/B 比率降低了 25.4%。第 10 周时,血浆 LPS/IgG 呈 116% 的增长趋势(p = 0.08)。血浆zonulin、DAO、组胺、DAO/组胺、LPS/IgG、LPS/IgA 或 LPS/IgM 均无明显变化。面部红斑在第 6 周时没有统计学差异,但在第 10 周时,红斑强度降低了 20% (p = 0.001)。在延长至第 14 周的患者中,红斑没有统计学变化:结论:补充抗菌植物补充疗法可能对氢亚型和硫化氢亚型 SIBO 有治疗潜力。此外,植物补充疗法可减少面部红斑、增加 SCFA 产菌、降低 F/B 比率并调节肠道通透性指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nutrients
Nutrients NUTRITION & DIETETICS-
CiteScore
9.20
自引率
15.30%
发文量
4599
审稿时长
16.74 days
期刊介绍: Nutrients (ISSN 2072-6643) is an international, peer-reviewed open access advanced forum for studies related to Human Nutrition. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
期刊最新文献
Application of Bioelectrical Impedance Analysis in Weight Management of Children with Spina Bifida. Association between Visceral Adiposity Index and Hyperuricemia among Steelworkers: The Moderating Effects of Drinking Tea. Caffeine Placebo Effect in Sport and Exercise: A Systematic Review. Mediterranean Diet Prior to Ischemic Stroke and Potential Circulating Mediators of Favorable Outcomes. Prognostic Characteristics of Metabolic Dysfunction-Associated Steatotic Liver in Patients with Obesity Who Undergo One Anastomosis Gastric Bypass Surgery: A Secondary Analysis of Randomized Controlled Trial Data.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1